Patents by Inventor David K. Grandy
David K. Grandy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090105347Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed.Type: ApplicationFiled: November 30, 2007Publication date: April 23, 2009Applicants: The Regents of the University of California, Oregon Health & Science UniversityInventors: Thomas S. Scanlan, Matthew E. Hart, David K. Grandy, James R. Bunzow, Mononori Miyakawa, Edwin Saavedra Tan, Katherine L. Suchland
-
Patent number: 7381542Abstract: The present invention relates to novel mammalian biogenic amine receptor proteins and genes that encode such proteins. The invention is directed toward the isolation and characterization of mammalian trace amine receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to rat and human homologues of a mammalian trace amine receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian trace amine receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian trace amine receptor proteins encoded therein.Type: GrantFiled: December 19, 2001Date of Patent: June 3, 2008Assignee: Oregon Health & Science UniversityInventors: James Bunzow, David K. Grandy, Mark Sonders
-
Patent number: 7355079Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.Type: GrantFiled: April 5, 2005Date of Patent: April 8, 2008Assignees: The Regents of the University of California, Oregon Health & Science UniversityInventors: Thomas S. Scanlan, Matthew E. Hart, David K. Grandy, James R. Bunzow, Motonori Miyakawa, Edwin Saavedra Tan, Katherine L. Suchland
-
Patent number: 7339079Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.Type: GrantFiled: June 17, 2005Date of Patent: March 4, 2008Assignees: The Regents of the University of California, Oregon Health & Science UniversityInventors: Thomas S. Scanlan, Matthew E. Hart, David K. Grandy, James R. Bunzow
-
Patent number: 7321065Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.Type: GrantFiled: April 16, 2004Date of Patent: January 22, 2008Assignees: The Regents of the University of California, Oregon Health & Science UniversityInventors: Thomas S. Scanlan, Matthew E. Hart, David K. Grandy, James R. Bunzow, Motonori Miyakawa, Edwin Saavedra Tan, Katherine L. Suchland
-
Patent number: 7022816Abstract: A mammalian D2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.Type: GrantFiled: August 21, 2001Date of Patent: April 4, 2006Assignee: Oregon Health and Science UniversityInventors: Oliver Civelli, James R. Bunzow, David K. Grandy, Curtis A. Machida
-
Patent number: 6979750Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.Type: GrantFiled: April 18, 2003Date of Patent: December 27, 2005Assignees: The Regents of the University of California, Oregon Health & Science UniversityInventors: Thomas S. Scanlan, Matthew E. Hart, David K. Grandy, James R. Bunzow
-
Patent number: 6783973Abstract: The present invention relates to novel mammalian catecholamine receptor proteins and genes that encode such proteins. The invention is directed toward the isolation and characterization of mammalian catecholamine receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to rat and human homologues of a mammalian catecholarnine receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian catecholamine receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian catecholamine receptor proteins encoded therein. The invention also provides methods for screening compounds in vitro that are capable of binding to the mammalian catecholamine receptor proteins of the invention, and further characterizing the binding properties of such compounds in comparison with known catecholamine receptor agonists and antagonists.Type: GrantFiled: September 12, 2000Date of Patent: August 31, 2004Assignee: Oregon Health & Science UniversityInventors: James R. Bunzow, David K. Grandy
-
Publication number: 20040142390Abstract: The present invention relates to novel mammalian catecholamine receptor proteins and genes that encode such proteins. The invention is directed toward the isolation and characterization of mammalian catecholamine receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to rat and human homologues of a mammalian catecholamine receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian catecholamine receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian catecholamine receptor proteins encoded therein. The invention also provides methods for screening compounds in vitro that are capable of binding to the mammalian catecholamine receptor proteins of the invention, and further characterizing the binding properties of such compounds in comparison with known catecholamine receptor agonists and antagonists.Type: ApplicationFiled: January 30, 2004Publication date: July 22, 2004Applicant: Oregon Health Sciences University, a non-profit organizationInventors: James R. Bunzow, David K. Grandy
-
Publication number: 20040072187Abstract: The present invention relates to novel mammalian biogenic amine receptor proteins and genes that encode such proteins. The invention is directed toward the isolation and characterization of mammalian trace amine receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to rat and human homologues of a mammalian trace amine receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian trace amine receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian trace amine receptor proteins encoded therein.Type: ApplicationFiled: August 4, 2003Publication date: April 15, 2004Inventors: James Bunzow, David K. Grandy, Mark Sonders
-
Publication number: 20030040022Abstract: A mammalian D2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.Type: ApplicationFiled: January 29, 2002Publication date: February 27, 2003Applicant: Oregon Health and Sciences UniversityInventors: Olivier Civelli, James R. Bunzow, David K. Grandy, Curtis A. Machida
-
Publication number: 20020123096Abstract: A mammalian D2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.Type: ApplicationFiled: August 21, 2001Publication date: September 5, 2002Applicant: Oregon Health Sciences University.Inventors: Olivier Civelli, James R. Bunzow, David K. Grandy, Curtis A. Machida
-
Patent number: 6406866Abstract: The present invention relates to a novel mammalian opioid receptor protein and ligands that bind to such proteins. The invention is directed toward the isolation, characterization and pharmacological use of an endogenous ligand that specifically binds to a novel mammalian opioid receptor protein heterologously expressed in mammalian cells. The invention specifically provides the isolated peptide ligand and analogues, derivatives and variants thereof. The invention specifically provides tyrosine substitution variants of the peptide ligand that specifically bind to the opioid receptor and can be radioiodinated. Also provided are methods of making such peptide ligands and methods of using the ligands for diagnostic and therapeutic uses and for the identification of other naturally-occurring or synthetic opioid receptor ligands.Type: GrantFiled: March 26, 1998Date of Patent: June 18, 2002Assignee: Oregon Health Sciences UniversityInventors: David K. Grandy, James R. Bunzow, Olivier Civelli, Rainer Klaus Reinscheid, Hans-Peter Nothacker, Frederick James Monsma
-
Patent number: 6342360Abstract: A mammalian D2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.Type: GrantFiled: January 27, 1999Date of Patent: January 29, 2002Assignee: Oregon Health & Science UniversityInventors: Olivier Civelli, James R. Bunzow, David K. Grandy, Curtis A. Machida
-
Patent number: 6280973Abstract: The present invention relates to a novel-mammalian methadone-specific opioid receptor protein and genes that encode such a protein. The invention is directed toward the isolation, characterization and pharmacological use of mammalian methadone-specific opioid receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to the rat homologue of the mammalian methadone-specific opioid receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian methadone-specific opioid receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian methadone-specific opioid receptor proteins encoded therein.Type: GrantFiled: February 22, 2000Date of Patent: August 28, 2001Assignee: Oregon Health & Science UniversityInventors: David K. Grandy, James R. Bunzow, Olivier Civelli
-
Patent number: 6277591Abstract: A mammalian D2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.Type: GrantFiled: June 7, 1995Date of Patent: August 21, 2001Assignee: Oregon Health Science UniversityInventors: Olivier Civelli, James R. Bunzow, David K. Grandy, Curtis A. Machida
-
Publication number: 20010010919Abstract: The present invention relates to a novel mammalian anti-opioid receptor protein (OFQR), peptide ligands (such as OFQ) that bind to OFQR, and methods of using the OFQ peptide and analogues to reverse the physiologic effects of opiates such as morphine. The isolation, characterization and pharmacological use of the endogenous peptide ligand is described. A particular embodiment of the OFQ peptide is a heptadecapeptide having an FGGF aminoterminal motif. The peptide specifically binds to an OFQ receptor protein heterologously expressed in mammalian cells. The peptide does not bind with high affinity to &mgr;, &dgr; or &kgr; receptors, but it antagonizes opioid mediated effects (such as analgesia and hypothermia) without increasing nociceptive sensitivity. Tyrosine substitution variants of the peptide ligand specifically bind to the opioid receptor and can be radioiodinated.Type: ApplicationFiled: October 13, 1998Publication date: August 2, 2001Inventors: DAVID K. GRANDY, JUDITH E. GRISEL, JEFFREY S. MOGIL, JAMES R. BUNZOW, OLIVIER CIVELLI, RAINER KLAUS REINSCHEID, HANS-PETER NOTHACKER, FREDERICK MONSMA
-
Patent number: 6028175Abstract: The present invention relates to a novel mammalian methadone-specific opioid receptor protein and genes that encode such a protein. The invention is directed toward the isolation, characterization and pharmacological use of mammalian methadone-specific opioid receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to the rat homologue of the mammalian methadone-specific opioid receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian methadone-specific opioid receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian methadone-specific opioid receptor proteins encoded therein.Type: GrantFiled: October 13, 1998Date of Patent: February 22, 2000Assignee: Oregon Health Science UniversityInventors: David K. Grandy, James R. Bunzow, Olivier Civelli
-
Patent number: 5880260Abstract: A mammalian D.sub.2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.Type: GrantFiled: June 7, 1995Date of Patent: March 9, 1999Assignee: Oregon Health Sciences UniversityInventors: Olivier Civelli, James R. Bunzow, David K. Grandy, Curtis A. Machida
-
Patent number: 5837809Abstract: The present invention relates to a novel mammalian opioid receptor protein and ligands that bind to such proteins. The invention is directed toward the isolation, characterization and pharmacological use of an endogenous ligand that specifically binds to a novel mammalian opioid receptor protein heterologously expressed in mammalian cells. The invention specifically provides the isolated peptide ligand and analogues, derivatives and variants thereof. The invention specifically provides tyrosine substitution variants of the peptide ligand that specifically bind to the opioid receptor and can be radioiodinated. Also provided are methods of making such peptide ligands and methods of using the ligands for diagnostic and therapeutic uses and for the identification of other naturally-occurring or synthetic opioid receptor ligands.Type: GrantFiled: August 11, 1995Date of Patent: November 17, 1998Assignee: Oregon Health Sciences UniversityInventors: David K. Grandy, James R. Bunzow, Olivier Civelli, Rainer Klaus Reinscheid, Hans-Peter Nothacker, Frederick James Monsma